The Europe Castrate-resistant Prostate Cancer Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026). Owing to the growing prevalence of CRPC, leading market players are expanding themselves into emerging economies by executing strategies like diversification of product portfolios. Moreover, companies invest heavily to accelerate advancement in the development of new medicines. Additionally, the expected launch of new products and increasing awareness of prostate cancer are likely to augment the market growth rate during the forecast period. Furthermore, the rising adoption of novel drugs and a solid pipeline are factors that propel market growth over the forecast period.
The increasing technological advancement in the diagnostic tests which detect prostate cancer will drive the growth of the castrate resistant prostate cancer market. Detection of prostate cancer is very important in order to provide treatment for the patients. With the emergence of more technical advanced equipment for detecting prostate cancer, the market growth will augment over the forecast years.
To detect castration-resistant prostate cancer, tumor marker, staging test biopsy, and prostate imaging are required. These technologies identify prostate cancer at early stages which gives more time to patients to get proper treatment. This further accelerates the growth of the Castrate-resistant Prostate Cancer market.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in Europe is expected to register a CAGR of 7.9% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Radiotherapy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Europe Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Europe Castrate-resistant Prostate Cancer Market by Therapy
4.1 Europe Hormonal Therapy Market by Country
4.2 Europe Immunotherapy Market by Country
4.3 Europe Chemotherapy Market by Country
4.4 Europe Radiotherapy Market by Country
Chapter 5. Europe Castrate-resistant Prostate Cancer Market by Country
5.1 Germany Castrate-resistant Prostate Cancer Market
5.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2 UK Castrate-resistant Prostate Cancer Market
5.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.3 France Castrate-resistant Prostate Cancer Market
5.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.4 Russia Castrate-resistant Prostate Cancer Market
5.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.5 Spain Castrate-resistant Prostate Cancer Market
5.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.6 Italy Castrate-resistant Prostate Cancer Market
5.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
TABLE 1 Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 2 Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 Europe Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 6 Europe Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 7 Europe Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 8 Europe Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 9 Europe Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 10 Europe Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 11 Europe Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 12 Europe Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 13 Europe Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 14 Europe Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 15 Germany Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 Germany Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 UK Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 20 UK Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 21 UK Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 22 UK Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 23 France Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 24 France Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 25 France Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 26 France Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 27 Russia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 28 Russia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 29 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 30 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 31 Spain Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 32 Spain Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 33 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 34 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 35 Italy Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 36 Italy Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 37 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 38 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 39 Rest of Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 40 Rest of Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 41 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 42 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 43 Key Information – Sanofi S.A.
TABLE 44 Key information –Johnson and Johnson
TABLE 45 Key Information – Pfizer, Inc.
TABLE 46 Key Information – Bayer AG
TABLE 47 Key Information – Abbott Laboratories
TABLE 48 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 49 Key Information – Northwest Biotherapeutics, Inc.
TABLE 50 Key Information – Active Biotech AB
TABLE 51 key information – Astellas Pharma, Inc.
TABLE 52 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research